상세정보
Export to Refworks부가기능
The Use of a TEC Kinase Inhibitor, Ibrutinib, for the Development of Immunotherapies Against Cancer and Leishmaniasis
상세 프로파일
| 자료유형 | 학위논문 |
|---|---|
| 서명/저자사항 | The Use of a TEC Kinase Inhibitor, Ibrutinib, for the Development of Immunotherapies Against Cancer and Leishmaniasis. |
| 개인저자 | Natarajan, Gayathri. |
| 단체저자명 | The Ohio State University. Microbiology. |
| 발행사항 | [S.l.]: The Ohio State University., 2016. |
| 발행사항 | Ann Arbor: ProQuest Dissertations & Theses, 2016. |
| 형태사항 | 134 p. |
| 기본자료 저록 | Dissertation Abstracts International 79-10B(E). Dissertation Abstract International |
| ISBN | 9780438092679 |
| 학위논문주기 | Thesis (Ph.D.)--The Ohio State University, 2016. |
| 일반주기 |
Source: Dissertation Abstracts International, Volume: 79-10(E), Section: B.
Adviser: Abhay Satoskar. |
| 요약 | Proteins belonging to the TEC family of kinases are critical for the function of immune cells. One of the kinases in this family, BTK (Bruton's tyrosine kinase), is required for the function of B cells. BTK also plays key roles during the pathog |
| 요약 | In addition to treating B cell malignancies, ibrutinib can potentially target other immune cells expressing BTK, such as dendritic cell (DCs). DCs, known as 'sentinels of the immune system', survey the body for the presence of 'danger signals' f |
| 요약 | Since ibrutinib effectively inhibits the function of B cells, it could also be expanded for the treatment of infectious diseases involving B cells. B cells contribute to susceptibility to the parasitic, vector-borne disease cutaneous leishmanias |
| 일반주제명 | Microbiology. Immunology. |
| 언어 | 영어 |
| 바로가기 | 
: 이 자료의 원문은 한국교육학술정보원에서 제공합니다. |
